CD95 Rs1800682a/g Variant and Tumor Risk in Asians: Evidence from a Meta-Analysis of 36 Case-Control Studies Containing 22 438 Samples

Cheng Jin,Xiaomin Wu,Yuanlong Gu,Fenglai Yuan,Qinghai Ye,Feng Dai,Lijie Zhu,Yuanyuan Mi
DOI: https://doi.org/10.12659/msm.892547
2015-01-01
Medical Science Monitor
Abstract:Background: The CD95 gene plays a key role in regulating cell growth and tumor genesis. To date, several publications have focused on the CD95 rs1800682A/G site polymorphism and various types of tumors in Asians; however, this association is still controversial and obscure. Therefore, a meta-analysis combined with all publications to clarify this association is necessary. Material/Methods: A search in the PubMed and SinoMed databases was performed to detect all relevant included publications. Odds ratio (OR) and 95% confidence intervals (CI) revealed association strengths. Results: Overall, 36 case-control studies were chosen based on the search criteria. There was no association of the CD95 rs1800682A/G site polymorphism with tumor risk in total and ethnicity subgroup analysis. However, further stratified analysis in the cancer subgroup revealed weakly significant associations in hepatocellular carcinoma (AA+AG vs. GG: OR=0.93, 95% CI=0.87-0.99, P=0.035; AG vs. GG: OR=0.89, 95% CI=0.80-0.99, P=0.036). Conclusions: The CD95 rs1800682A/G site polymorphism may be associated with hepatocellular carcinoma susceptibility. Further large-scale and well-designed studies regarding tumor types and ethnicities are still required to confirm our results.
What problem does this paper attempt to address?